Sipuleucel-T

Introduction Overview

Generic Name

sipuleucel-T

Brand Name

Provenge

Dosage Form

Intravenous infusion of autologous activated immune cells

Drug Class

Therapeutic vaccines

Pharmacokinetics

Absorption:
Sipuleucel-T is a unique biological therapy administrated by intravenous infusion as an autologous cellular product; hence it does not follow classical absorption pathways characteristic of small molecule drugs. The process involves ex vivo activation of the patient's own antigen-presenting cells (APCs) through leukapheresis, which are then reinfused into the patient. Since the product consists of activated immune cells, absorption per se is not applicable in the conventional pharmacokinetic sense. Instead, efficacy depends on successful activation and reinfusion of the therapeutic cells and their subsequent interaction with the immune system.

Distribution:
Following intravenous infusion, the activated antigen-presenting cells circulate systemically, homing to lymphoid tissues where they present the prostate antigen (prostatic acid phosphatase fused to granulocyte-macrophage colony-stimulating factor) to T-cells, stimulating a targeted immune response. Due to the cellular nature of the product, data on classical plasma protein binding or volume of distribution are not applicable. The biodistribution primarily depends on the trafficking of antigen-presenting cells and the subsequent activation and proliferation of cytotoxic T-lymphocytes within lymphoid organs.

Metabolism:
As an immunotherapy composed of activated white blood cells, sipuleucel-T undergoes the normal physiological processes governing white blood cell lifespan and clearance once reinfused. The fusion protein used for activation is metabolized intracellularly by antigen-presenting cells following antigen processing pathways. The immune response elicited involves clonal expansion and activity of T-cells, which is mediated by standard cellular metabolic pathways. There is no hepatic or renal metabolism involvement typical of small molecule drugs.

Elimination:
Elimination of sipuleucel-T involves natural cell death and immune regulation mechanisms. The activated immune cells have a limited lifespan and are removed via normal cellular turnover and clearance by the reticuloendothelial system. There is no renal or biliary excretion. The duration of immune activation may persist beyond the physical presence of infused cells due to immune memory formation. Clinical significance lies in the immune system's long-lasting antitumor responses rather than drug clearance kinetics.

Dosage Forms

Available Dosage Forms:
Provenge is uniquely formulated as an autologous cellular immunotherapy product. It is supplied as a bag containing 50 million CD54+ activated autologous peripheral blood mononuclear cells suspended in 250 mL of solution for intravenous infusion. This formulation is patient-specific and prepared following leukapheresis collection of the patient's immune cells.

Dosages for Adults and Adolescents:
The standard dosing regimen for Provenge involves three complete infusions administered approximately two weeks apart. Each infusion requires leukapheresis roughly three days before the infusion to harvest immune cells for activation ex vivo. Each dose consists of an intravenous infusion over about 60 minutes of the activated cellular product containing approximately 50 million activated antigen-presenting cells. Premedication with acetaminophen and antihistamines is recommended approximately 30 minutes prior to infusion to reduce the risk of infusion reactions. Post-infusion observation of at least 30 minutes is necessary to monitor for adverse reactions.

Specific Patient Populations:
Provenge is indicated specifically for men with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. The therapy is autologous, meaning it is derived individually from each patient’s own immune cells, so the dose and formulation are inherently patient-specific. There is limited data on pediatric, adolescent, or female patients as the indication is for advanced prostate cancer in men. Use in patients with compromised immune systems requires physician assessment, and monitoring for history of cardiac or respiratory disease is important due to potential infusion-related adverse reactions.
Given the autologous nature, the product is intended only for the individual from whom the cells were collected, and timing between leukapheresis and infusion must be strictly followed; otherwise, the product cannot be used.

Mechanism Of Action

Sipuleucel-T (Provenge) is an autologous cellular immunotherapy designed to stimulate the patient’s immune system specifically against prostate cancer cells expressing prostatic acid phosphatase (PAP), an antigen commonly found on prostate cancer cells. The mechanism starts with leukapheresis, where peripheral blood mononuclear cells—including antigen-presenting cells (APCs)—are collected from the patient. These cells are then exposed ex vivo to a fusion protein composed of PAP linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), which activates the APCs to present PAP antigens effectively.

Once reinfused into the patient, these activated APCs interact with T-cells in the lymphoid tissues, leading to priming and activation of cytotoxic T-lymphocytes (CTLs) specific for PAP-expressing cancer cells. This promotes an adaptive immune response capable of selectively targeting and destroying prostate cancer cells exhibiting the PAP antigen. The therapy harnesses the body's own immune surveillance mechanisms to recognize and attack tumor cells without direct cytotoxic agents.

This immunotherapeutic strategy uniquely leverages the specificity of an antigen-targeted cellular vaccine to circumvent tumor immune evasion. Compared to other immunotherapies like checkpoint inhibitors, Provenge initiates a targeted antigen-specific cellular immune response rather than broadly removing inhibitory immune checkpoints. Clinical studies have demonstrated that this leads to a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer, validating the clinical immunologic mechanism.

Research further indicates that the mechanism induces a durable immune memory, potentially sustaining antitumor activity beyond the treatment course. The customized preparation from the patient’s own cells reduces risks of alloimmune reactions, enabling repeated dosing. Importantly, the ex vivo activation enhances the quantity and quality of antigen presentation, which is critical for effective T-cell priming and subsequent antitumor effect. This personalized immunotherapy marks a distinct paradigm in cancer treatment compared to conventional chemotherapy or hormonal therapies.

Pharmacological Actions

Induces a patient-specific immune response against prostate cancer cells expressing prostatic acid phosphatase antigen.
Activates antigen-presenting cells ex vivo to enhance T-cell priming upon reinfusion.
Stimulates cytotoxic T-lymphocyte activity targeted to prostate cancer cells, promoting tumor cell lysis.
Functions as an autologous therapeutic cancer vaccine.
Does not directly kill cancer cells but relies on immune-mediated cytotoxicity.
Invokes long-lasting immunologic memory for sustained antitumor effect.
Bypasses tumor immune evasion through targeted antigen presentation.
Exhibits acceptable tolerability with immune modulation rather than cytotoxicity.
Requires leukapheresis for cell collection, followed by ex vivo processing.
Pre-medication with acetaminophen and antihistamine minimizes acute infusion reactions.
Distinct from hormonal therapies and chemotherapy, functioning via immune activation.
Improves overall survival in metastatic castrate-resistant prostate cancer patients.
Demonstrates specificity with limited off-target immunologic effects.
Activates innate and adaptive immune pathways via antigen-presenting and effector T-cells.
Requires precise coordination of cell collection and infusion for efficacy.

Therapeutic Or Clinical Uses

Treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer in men.
Immunotherapy option after failure or intolerance of conventional prostate cancer treatments.
Used as a second-line or subsequent therapy for advanced prostate cancer.
Alternative to chemotherapy and hormone therapy in selected patients.
Indicated specifically for prostate cancer expressing prostatic acid phosphatase.
Suitable for patients who have adequate performance status to undergo leukapheresis.
Treatment aimed at extending overall survival in metastatic prostate cancer.
Can be combined with supportive therapies to manage disease symptoms.
Option for patients seeking immunologic approaches over cytotoxic agents.
Utilized when cancer is resistant to castrate levels of testosterone.
Indicated for autologous use only; not suitable for allogeneic application.
May be chosen for patients with minimal tumor burden suitable for immunotherapy.
Used in clinical settings with facilities capable of leukapheresis and cell processing.
Treatment schedule consists of three doses approximately two weeks apart.
Chosen for its favorable toxicity profile compared to traditional chemotherapies.

Side Or Adverse Effects

Infusion-related reactions such as chills, fever, and fatigue occurring during or within 24 hours post-infusion.
Headache of variable severity.
Nausea and gastrointestinal discomfort.
Back pain during or after infusion.
Joint pain and myalgia.
Dizziness or light-headedness, sometimes leading to syncope.
Tachycardia or palpitations (fast or irregular heartbeats).
Signs of allergic reactions including hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.
Local site reactions associated with leukapheresis catheter insertion including redness or pain.
Rare but severe infusion reactions requiring immediate medical attention.
Symptoms mimicking stroke such as sudden numbness, weakness, or vision disturbances warrant urgent evaluation.
Signs of infection at infusion or leukapheresis sites.
Possible development of blood clots manifesting as limb swelling or chest pain.
Anxiety, confusion, and neurologic symptoms reported in some cases.
Fever and chills common but generally self-limiting after infusion.

Precautions

Assess cardiac history prior to therapy due to risk of infusion-related cardiopulmonary events.
Evaluate history of stroke or cerebrovascular disease before administration.
Screen for respiratory diseases such as COPD or asthma which may increase infusion reaction risk.
Strict adherence to cell collection and infusion scheduling to ensure product viability.
Use premedication with acetaminophen and antihistamines to reduce infusion reactions.
Monitor patients closely during and at least 30 minutes after infusion for adverse events.
Avoid infusion interruptions or delays that could invalidate the prepared product.
Assess immune status; cautious use in immunocompromised individuals or those on immunosuppressants.
Not recommended for use in females or pediatric patients as studied only in adult males with prostate cancer.
Ensure facilities have capability for leukapheresis and sterile cell processing.
Instruct patients to report any neurological or cardiopulmonary symptoms promptly.
Consider risk-benefit in patients with significant comorbidities.
Avoid concurrent use of systemic steroids or immunosuppressants that may reduce efficacy.
Evaluate for active infections before initiating treatment.
Educate patients about potential side effects and need for close medical observation.

Warnings

Provenge may cause severe infusion reactions including fever, chills, dyspnea, and hypotension.
Patients with heart disease or prior stroke history are at increased risk of adverse events during infusion.
Monitor for signs of a stroke such as sudden weakness, numbness, or speech difficulties.
Potential for serious allergic reactions or anaphylaxis exists.
Do not use the prepared product if infusion appointment is missed; discarded product cannot be reused.
Use caution in patients with compromised lung function due to risk of respiratory complications.
Premedication is essential to minimize acute infusion side effects.
Adherence to infusion schedule is critical; disruptions may lead to loss of therapeutic efficacy.
Infection risk at leukapheresis and infusion sites requires vigilant monitoring.
Patients should be observed for at least 30 minutes post-infusion for early detection of adverse events.
This product is intended only for autologous use; do not administer to other patients.
Pregnancy category is not well established; avoid use during pregnancy.
Risk of blood clots associated with therapy has been reported.
Use in immune suppressed or transplanted patients requires specialized monitoring.
Risk of delayed neurologic or cardiopulmonary events necessitates prompt medical evaluation.

Contraindication

Known hypersensitivity to sipuleucel-T or components of the product.
Patients who cannot undergo leukapheresis or do not have adequate peripheral blood mononuclear cells for product preparation.
Patients with active systemic infections that contraindicate leukapheresis.
Use is contraindicated if patient is unable to comply with the strict treatment and infusion schedule.
Contraindicated in patients with known hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Patients with severe cardiac, pulmonary, or neurological conditions precluding safe infusion.
Contraindicated in female and pediatric populations due to lack of efficacy and safety data.
Not to be administered with systemic immunosuppressive therapies that block immune activation.
Patients with uncontrolled autoimmune diseases where immune activation may exacerbate symptoms.
Contraindicated if infusion product has been compromised due to mishandling or delayed administration.
Patients with inadequate performance status that precludes leukapheresis or toleration of infusion.
Not suitable for patients with known hypersensitivity reactions to previous immunotherapies of this kind.
Contraindicated in those with severe allergic reactions to antihistamine or acetaminophen premedication components.
Not intended for use as prophylactic vaccination or in non-prostate cancer malignancies.
Patients with bleeding disorders that increase risk from leukapheresis catheter insertion.

Drug Interactions

Concurrent administration of immunosuppressive agents such as corticosteroids (e.g., prednisone) may reduce the efficacy of Provenge by diminishing immune activation.
Cancer chemotherapy agents that suppress bone marrow and immune cell populations could interfere with the preparation and function of the autologous cellular product.
Medications that impair leukocyte function or proliferation may negatively affect treatment response.
Vaccinations given concurrently should be assessed carefully to avoid immune system overactivation or interference.
Other immunomodulatory drugs may alter immune response dynamics and should be used cautiously.
Use of immunosuppressants for transplant rejection prevention might reduce therapeutic efficacy.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are not known to have significant interactions but should be used cautiously to manage side effects.
No direct pharmacokinetic interactions due to the cellular nature of Provenge; however, systemic immune modulators can affect clinical outcomes.
Patients on anticoagulants require monitoring during leukapheresis due to blood collection procedure.
Drugs that cause fever or cytokine release syndrome may complicate differentiation of side effects.
Vitamins and herbal supplements affecting immune function should be reported to the treating physician.
Medications causing sedation or hypotension may increase infusion reaction risks.
Potential interaction with agents affecting cytokine signaling pathways is theoretical but warrants caution.
Avoid concurrent participation in other investigational immunotherapy trials without physician consent.
Ensure careful medication reconciliation to identify and manage potential additive immune-related adverse effects.

Preparations Of The Drug

Provenge is prepared as an autologous cellular immunotherapy product by ex vivo activation of the patient’s antigen-presenting cells.
Peripheral blood mononuclear cells are collected via leukapheresis approximately three days prior to each infusion.
Collected cells are incubated with a recombinant fusion protein containing prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune cells.
Activated cells are suspended in 250 mL infusion bags containing approximately 50 million CD54+ activated cells per dose.
The activated cell product is then shipped under controlled conditions and infused intravenously into the patient over approximately 60 minutes.
Premedication with acetaminophen and an antihistamine is recommended prior to infusion to minimize infusion reactions.
The entire process requires specialized laboratory facilities for sterile cell processing and quality assurance.
Strict scheduling between leukapheresis and infusion is critical; delays may render the product unusable.
Each dose is patient-specific and cannot be interchanged between individuals.
The product should be stored and handled according to manufacturer and institutional protocols to maintain cell viability.
Healthcare providers should monitor patients closely during and after infusion for adverse events.
Provenge is intended for intravenous use only; a cell filter should not be used during infusion.
Proper documentation and chain-of-custody procedures are essential throughout preparation and administration.
The preparation does not involve viral vectors or genetic modification, relying on protein-induced activation.
Post-infusion monitoring includes observation for infusion-related side effects and potential immune-mediated adverse reactions.